Adma Biologics Inc.

It earns most of its revenue from one-time product sales, paid after delivery within a set window, with a much smaller share from contract manufacturing and laboratory services, sales of intermediate plasma fractions, and licensing one product to an outside partner. Revenue and the receivables owed to it have both grown in each of the last several years, consistent with a business extending more of its own credit terms as it grows rather than collecting entirely upfront.

Its return and margin measures sit in the upper range among companies whose products must clear a regulatory approval step before they can be sold, and it has grown revenue and operating income every year over several consecutive years. Capital spending has run well ahead of depreciation, a configuration CompanyGraph associates with a still-expanding or young asset base, though the same pattern can also reflect an asset-light business or a depreciation policy that understates real wear. By its own account, growth depends on expanding plasma collection, manufacturing capacity and staffing, with each expansion needing its own regulatory sign-off rather than being demand-led alone, and its bottom-line result has not moved in lockstep with that operating growth every year.

It relies on third-party plasma suppliers and counterparties named in its own filings, including Grifols Worldwide Operations, KEDPlasma and Biotest Pharmaceuticals, and on outside contractors for filling, packaging, labeling and testing, rather than performing every step itself. Notably, the name Grifols appears in the same filings both among these supply counterparties and among the competitors it names elsewhere, so at least one input relationship runs through a company that also appears on its competitor list. It also depends on a continuing supply of regulator-approved plasma from paid donors, on regulatory licensing to keep its plants and collection centers operating, and on its Boca facility, which it has said has no alternative or replacement arrangement if lost. CompanyGraph separately maps it as sitting downstream of a small number of industries that feed its inputs.

A small number of named distributors, including BioCare and CuraScript SD Specialty Distribution, fulfill most of its orders to hospitals, physician offices, clinics and specialty treatment centers. Biotest AG separately holds the exclusive right to market and sell its ASCENIV product across Europe and specified countries in Northern Africa and the Middle East. Because those buyers in turn serve immunocompromised patients with an ongoing therapeutic need, concentration sits at the distributor layer even though the underlying need originates with patients.

By its own account, it is one of a small number of producers of plasma-derived products in the United States, naming CSL Behring, Grifols and Takeda alongside itself, which describes a concentrated market rather than one with many competing producers. The company also describes its donor-selection criteria, formulation methods and testing standards as proprietary, though whether those specific methods are actually difficult for its named competitors to replicate is not something CompanyGraph can measure. Set against the wider population of companies whose products must clear a regulatory approval step before they can be sold, this business sits within a much larger peer group at that broader level, so the scarcity is a feature of the plasma-products market specifically, not of its broader regulatory category.

The general pattern for this kind of business is that revenue depends on clearing a long, binary regulatory approval step before it can be earned at all. This company's own account describes a related but distinct limit for its already-approved products: growth requires expanding plasma collection, manufacturing capacity, staffing and systems, and each of those expansions itself needs regulatory sign-off, so the constraint sits on approval for added capacity rather than on winning first approval. It also states that it does not currently see itself as limited by demand or by supply, while warning it could become supply-limited if it cannot keep obtaining enough regulator-approved plasma and other raw material.

By its own account, several single points of exposure sit close together: its Boca facility, for which it says there is no alternative or replacement arrangement if lost to a casualty event; dependence on outside parties for filling, packaging, testing and labeling that it does not control directly; reliance on a small number of customers that account for a concentrated share of its business; and a continued supply of regulator-approved plasma. It names sustaining profitability and positive cash flow, and passing ongoing regulatory inspection, among the pressures it lists first, which suggests these are the risks it treats as most immediate to its own operation.

Its own filings name the FDA, through the agency's biologics review center, as the regulator governing its products, manufacturing facility and plasma centers, operating under a federal biologics license, with a South Korean regulator also named in connection with its filings. It lists passing regulatory inspection and sustaining profitability and positive cash flow among the pressures it flags first, alongside the risk that outside parties it depends on for filling, packaging, testing and labeling do not perform as needed. More broadly, this sits in a category of business where a product earns nothing until it clears a regulatory approval step, a general feature of that category rather than something separately measured about this company's own pipeline.